41 studies found for:    MAPK8
Show Display Options
Rank Status Study
1 Terminated A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: vincristine
2 Terminated Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Condition: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Intervention: Drug: plitidepsin
3 Completed
Has Results
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Condition: Non-Small-Cell Lung Carcinoma
Intervention: Drug: BAY 43-9006 (Sorafenib)
4 Recruiting Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Vemurafenib (All Groups);   Drug: Vemurafenib (Post Surgery) - Group A + C;   Other: Post Surgery - Group B
5 Completed A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
Condition: Rheumatoid Arthritis
Interventions: Drug: P38 Inhibitor (4);   Drug: Placebo
6 Completed Efficacy Study in Lumbosacral Radiculopathy
Conditions: Pain, Neuropathic;   Lumbosacral Radiculopathy
Interventions: Drug: Placebo;   Drug: GS856553
7 Recruiting The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
Condition: Asthma
Interventions: Drug: Simvastatin;   Drug: B1-6-12
8 Completed Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Semapimod
9 Completed A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: P38 Inhibitor (4);   Drug: Placebo
10 Recruiting A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
Condition: Melanoma
Intervention: Drug: Trametinib (2mg)/Digoxin (.25mg)
11 Recruiting A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Condition: Acute Coronary Syndrome
Interventions: Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
12 Completed SB-681323-Methotrexate Interaction Study
Condition: Arthritis, Rheumatoid
Intervention: Drug: SB-681323 oral tablets
13 Terminated A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: ARRY-371797, p38 inhibitor; oral;   Drug: Placebo; oral
14 Recruiting Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
Conditions: Gastric Cancer;   Oesophageal Cancer;   Breast Cancer;   Squamous Cell Carcinoma of the Lung
Intervention: Drug: AZD 4547
15 Completed A Safety Study of ARRY-371797 in Healthy Subjects
Condition: Healthy
Interventions: Drug: ARRY-371797, p38 inhibitor; oral;   Drug: Placebo; oral
16 Completed A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Conditions: Pulmonary Disease, Chronic Obstructive;   Chronic Obstructive Airway Disease
Interventions: Drug: GW856553;   Drug: Placebo;   Drug: Seretide
17 Completed Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: SCIO-469;   Drug: SCIO-469 and bortezomib
18 Completed A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Condition: Acute Coronary Syndrome
Interventions: Drug: GW856553;   Drug: Placebo
19 Completed Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects
Condition: Healthy
Interventions: Drug: BIBR 796 BS, low dose;   Drug: BIBR 796 BS, high dose;   Drug: Placebo;   Drug: Lipopolysaccharide
20 Completed Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Conditions: Carcinoma, Squamous;   Head and Neck Cancer;   Oral Cancer;   Laryngeal Cancer;   Pharyngeal Cancer
Interventions: Drug: Bortezomib (Velcade, PS-341);   Drug: Cetuximab;   Drug: Cisplatin;   Procedure: Radiation Therapy

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years